scPharmaceuticals Inc. (SCPH) has sought FDA approval to expand the use of its lead product Furoscix to include New York Heart Association Class IV heart failure patients and a decision is scheduled for August 2024. Furoscix is supplied as a kit, which includes an On-Body Infusor to deliver the medicine just under the skin and a Prefilled Cartridge, which contains the medicine Furosemide. Furoscix is already approved for the at-home treatment of congestion due to fluid overload in adults with New York Heart Association Class II/III chronic heart failure. The product generated revenue of $6.1 million for the first quarter of 2024, compared to $2.1 million in the year-ago quarter.As per the New York Heart Association (NYHA) Functional Classification, heart failure patients under Class IV category will experience symptoms even at rest and any physical activity causes further discomfort. (Source American Heart Association).SCPH closed Friday’s (Jul.26, 2024) trading at $4.94, down 0.80%.